Skip Navigation



Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Musculoskeletal | Family Medicine
Disease Category: Multiple Sclerosis
Location: United States, CO

Clinical Trial Details


Research Study Summary

New Investigational Medication for Relapsing Remitting Multiple Sclerosis (RRMS) who have had a documented relapse in the last year


This is a 12 month study to compare the safety and efficacy of 2 doses of Fingolimod (0.25mg and 0.5mg) every day vs Copaxone 20mg SC every day for patients with RRMS.

Patient Inclusion Criteria:

  • 18-65
  • 1 documented relapse in the last year
  • NO monoclonal antibodies within 6 months prior to start of study medication
  • NO varicella zoster
  • Heartrate must be greater than 45/bpm
  • NO uncontrolled diabetes with HbA1c >7%
  • Cannot have positive Hepatitis A, B, C and E

To Learn more

Both Male and Female


18 to 65 Years

Overall Status



12 Months

Facility Type



Alpine Clinical Research Center
1000 Alpine Avenue , Suite 200
Boulder, CO 80304
Phone: 303-443-7229

View Map

Research Center Information: Alpine Clinical Research Center

CW ID: 182097

Date Last Changed: July 18, 2013

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.